Dermatological Drugs Market Forecast 2014-2024

Dermatological Drugs Market Forecast 2014-2024

English
13 Pages
Read
Download
Downloading requires you to have access to the YouScribe library
Learn all about the services we offer

Description

Dermatological Drugs Market ForecastDermatological Drugs Market Forecast 2014-2024 PR Newswire LONDON, April 22, 2014 Future Prospects for Leading Companies Dermatological drugs - new study showing you trends, R&D progress, and predicted revenues Where's the dermatological drugs market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there. Our 272-page report provides 169 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market. Forecasts from 2014-2024 and other analyses show you commercial prospects Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales: • Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc., Knoxville, Tennessee, USA • Dr.

Subjects

Informations

Published by
Published 22 April 2014
Reads 31
Language English
Report a problem
Dermatological Drugs Market Forecast 2014-2024

PR Newswire


Future Prospects for Leading Companies 

Dermatological drugs - new study showing you trends, R&D progress, and predicted revenues
Where's the dermatological drugs market heading? Visiongain's brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

Our 272-page report provides 169 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects
Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you will find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter's Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of four exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales:
• Mr Peter R. Culpepper, CFO/COO, Provectus Biopharmaceuticals, Inc., Knoxville, Tennessee, USA
• Dr. Mike Bastian, Business Development Manager, Birken AG, Niefern-Öschelbronn, Germany
• Dr Steven Feldman, Director of the Phototherapy Treatment Center, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA
• Professor Hermann Lübbert, PhD, Chief Executive Officer, Biofrontera AG, Leverkusen, Germany

Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, you see forecasts to 2024 for these five submarkets:
• Psoriasis
• Skin infection drugs
• Acne
• Dermatitis
• Other treatments.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

See revenue forecasts for products
How will leading drugs perform to 2024 at world level? Our study forecasts sales of 28 products, including these brands:
• Humira
• Enbrel
• Stelara
• Cubicin
• Zyvox
• Claravis
• Epiduo
• Bepanthen
• Protopic

Discover how high revenues can go. You will see what's happening, understanding trends, challenges and opportunities.

Our analysis also breaks the main world forecast into geographical markets.

What are the prospects in the leading regions and countries?
In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:
• US
Japan
China
Germany
France
• UK
Italy
Spain
India
Brazil
Russia
Mexico
• Rest of the World

There will be growth in established pharma markets and in developing countries. Our analyses show that India, Brazil, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth
Overall world revenue for dermatological drugs will reach $24.1bn in 2014, our work forecasts. We predict steady revenue growth from 2014 to 2024. Rising demand for dermatological drugs, expanding healthcare coverage, the success of biological drugs and antibacterial drug resistance will increase sales to 2024.

Our work shows you what organisations hold greatest potential. See profiles of 6 leading companies, including these:
• Galderma
• Johnson & Johnson
• AbbVie
• GSK
• Pfizer
• LEO Pharma

A company profile gives you the following information:
• Revenue forecast for dermatological drugs from 2014 to 2024
• Discussion of a company's activities and outlook
• Recent financial results
• Assessment of recent developments - mergers and acquisitions (M&A), new products, and collaborations, including alliances, partnerships and joint ventures

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

To see a report overview please email Sara Peerun on sara.peerun@visiongainglobal.com

Research and development - assess innovation, trends and possibilities
What about R&D - the pipeline for new drugs? You will see trends for these areas:
• Psoriasis
• Skin infection drugs
• Acne
• Dermatitis
• Other progress in dermatology.

Our study also discusses these agents and technologies, among others:
• Drug delivery
• Oral drug candidates
• Novel small molecules
• Photodynamic therapy.

Dermatology holds strong, promising R&D. Novel compounds and new formulations with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues.

What issues will affect the dermatological drugs industry?
Our new report discusses issues and events affecting the dermatological drugs market. You will find discussions, including qualitative analyses:
• Increasing demand for dermatological drugs due to demographic trends
• A strong R&D pipeline
• Patent expiry and generic competition
• Growth areas such as skin infections, onychomycosis and melanoma
• Advances in topical drug delivery
• Personalised dermatology and genomics
• Pricing and reimbursement issues

You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.

How the Dermatological Drugs: World Market Prospects 2014-2024 & Future Prospects for Leading Companies report helps you
In summary, our 272-page report gives you the following knowledge:
Revenues forecast to 2024 for the world dermatological drugs market and 4 product categories (therapeutic classes) market - discover the industry's prospects, finding promising places for investments and revenues
Revenue forecasts to 2024 for the leading 12 national markets - US, Japan, China, Germany, France, UK, Italy, Spain, India, Brazil, Russia, Mexico and Rest of the World
Assessment of 6 leading companies - hear about products, results and strategies including revenue forecasts for dermatological drugs to 2024
Predicted revenues of 28 leading drugs to 2024 - see potentials of top products
Review of R&D pipelines - investigate developmental trends and progress
Discussion of what stimulates and restrains companies and the market
Prospects for established firms and those seeking to enter the market
View opinions from our survey, seeing interviews with authorities

You will find quantitative and qualitative analyses with independent predictions. You will receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our survey you are less likely to fall behind in knowledge or miss opportunity. See how you could benefit your research, analyses, and decisions. Also see how you can save time and receive recognition for commercial insight.

Visiongain's study is for everybody needing commercial analyses for the dermatological drugs market and leading companies. You find data, trends and predictions. Please order our report now.

To request an exec summary of this report please email Sara Peerun at            sara.peerun@visiongainglobal.com or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1242/Dermatological-Drugs-Market-Forecast-2014-2024

Companies Listed in this report: 

Abbott (split from Abbott Laboratories)
AbbVie
AbGenomics
Actavis
Actelion
AET BioTech
Affinium
AiCuris
Alembic
Alkem Laboratories
Allergan
Almirall
Amgen
Anacor Pharmaceuticals
AndroScience Corp
AnGes MG
Anterios
Apeiron Biologics
ApoPharma
Ascend Therapeutics
Astellas
Astion Pharma
AstraZeneca
Asubio Pharma (part of Daiichi Sankyo)
Atrix Laboratories (acquired by QLT Inc.)
Aurinia (formerly Isotechnika)
Aurobindo Pharma
Ausio Pharmaceuticals
Barr Laboratories (part of Teva)
Basilea Pharmaceutica
Bayer
Berg Pharma
Bertek Pharmaceuticals (part of Mylan)
Biocon
Biofrontera
Biotest AG
Biovail Laboratories (part of Valeant)
BioVex Group (acquired by Amgen)
BioXpress Therapeutics
Birken AG
Boehringer Ingelheim
Braintree Laboratories
Bristol-Myers Squibb
Bübchen (division of Nestlé)
Cadila Healthcare (part of Zydus Cadila)
CalciMedica
Can-Fite BioPharma
Cardinal Health
Causa Research
Celgene
Cellceutix
Celltech (acquired by UCB Pharma)
Celltrion
Celsus Therapeutics
Cempra
Centocor Ortho Biotech (part of Johnson & Johnson)
Cipher Pharmaceuticals
Cipla
Circassia
CollaGenex (acquired by Galderma)
Compañía Internacional de Comercio, S.A.P.I. de C.V. (CISCA) (acquired by Taisho)
Convoy Therapeutics
Cosmo Pharmaceuticals
Creabilis Therapeutics
Cubist Pharmaceuticals
Cutanea Life Sciences
Daiichi Sankyo
DAVA Pharmaceuticals
Delenex Therapeutics
Dermik (Sanofi division acquired by Valeant)
Dermira Inc.
Dow Pharmaceutical Sciences (part of Valeant)
Dr. Reddy's Laboratories
Durata Therapeutics
Eisai
Eli Lilly
Elorac
Foamix
Fortuderm
Forward Pharma
Fougera Pharmaceuticals (acquired by Novartis)
Fujifilm
Fujisawa Healthcare
Furiex Pharmaceuticals
G&E Herbal Biotechnology
G&W Laboratories
Galderma (now part of Nestlé)
Galderma Laboratories (US subsidiary of Galderma)
Gene Signal
Genentech (subsidiary of Roche)
Genpharm
Genzyme (subsidiary of Sanofi)
Glenmark Pharmaceuticals
Grupo Imperial (acquired by Taisho)
GSK
Hanwha Pharma
Heritage Pharmaceuticals
Hospira
Human Genome Sciences (subsidiary of GSK)
Idera Pharmaceuticals
Immune Response BioPharma, Inc.
Immunex (acquired by Amgen)
Impax Laboratories
Incyte
Innovaderm Research
Instituto Terapeutico Delta Ltda (acquired by Valeant)
Intrepid Therapeutics
Janssen (part of Johnson & Johnson)
Janssen Biotech (part of Johnson & Johnson)
Johnson & Johnson
Jubilant Life Sciences
Kosei (acquired by Taisho)
Kuhnil Pharma
KV Pharmaceutical
Kyowa Hakko Kirin
Laboratorios Kendrick (acquired by Sanofi)
LEO Foundation (LEO Pharma holding company)
LEO Pharma
L'Oréal
Lupin
Maruho
Matrix Laboratories (part of Mylan)
Mayne Pharma
McNeil Consumer Healthcare (part of Johnson & Johnson)
Meda AB
Medicis (part of Valeant)
Medison Pharma
Melinta Pharmaceuticals (formerly Rib-X)
Merck & Co.
Mitsubishi Tanabe
Moleculin
MorphoSys
Mycenax Biotech
Mylan Pharmaceuticals
Nabriva Therapeutics
NanoBio Corporation
Nestlé
NovaBay Pharmaceuticals
Novartis
Nycomed (part of Takeda)
OphthaliX (subsidiary of Can-Fite BioPharma)
Par Pharmaceutical
Paratek Pharmaceuticals
Peplin (acquired by LEO Pharma)
Perrigo
Pfizer
Pharmacia (part of Pfizer)
PharmaPraxis
Photocure
Pierre Fabre Medicament
Pliva Hrvatska (part of Teva)
PreCision Dermatology (acquired by Valeant)
Provectus Biopharmaceuticals
QLT Inc.
Q-Med (acquired by Galderma)
Ranbaxy (now part of Sun Pharma)
Regeneron
Roche
Rochester Drug Cooperative
Roxane Laboratories (part of Boehringer Ingelheim)
Sandoz (division of Novartis)
SangStat
Sanofi
Sanofi-Pasteur (vaccines division of Sanofi)
Schering-Plough (acquired by Merck & Co.)
Shanghai Celgen Bio-pharmaceutical
Shanghai CP Guojian Pharmaceutical
Shape Pharmaceuticals
Shionogi
Sidmak Laboratories
Sol-Gel Technologies
Stiefel Laboratories (acquired by GSK)
Sunovion Pharmaceuticals (part of Dainippon Sumitomo)
Switch Biotech
Synthes Inc. (part of Johnson & Johnson)
Taisho
Takeda Pharmaceuticals
Targanta Therapeutics (acquired by The Medicines Company)
Taro Pharmaceutical Industries
Tecnofarma (acquired by Valeant)
Telormedix
Teva
The Medicines Company
Therapeutics, Inc.
Theravance
Tolmar Inc.
Topica Pharmaceuticals
Tribute Pharmaceuticals
Trius Therapeutics (acquired by Cubist)
TTY BioPharm
UCB Pharma
Valeant
Vatera Healthcare Partners
VBL Therapeutics
Vicuron (acquired by Durata)
Vidara Therapeutics
ViiV Healthcare (GSK/Pfizer joint venture)
ViroBay
Vitacilina Corporation of America (VitaCorp) (acquired by Taisho)
Warner Chilcott (acquired by Actavis)
Watson Laboratories (part of Actavis)
Watson Pharmaceuticals (now Actavis)
Welichem Biotech
Wockhardt
Wyeth (part of Pfizer)
XBiotech
XenoPort
Xoma
Zydus Cadila